# | Biosimilar | Applicant | Reference Product | aBLA Approval | US Launch? | Pending BPCIA Litigation? |
1 | ZARXIO® (filgrastim-sndz) | Sandoz | NEUPOGEN® | Mar. 6, 2015 | Sept. 3, 2015 | Amgen v. Sandoz |
2 | INFLECTRA® (infliximab-dyyb) | Celltrion | REMICADE® | Apr. 5, 2016 | Late 2016 | Janssen v. Celltrion |
3 | ERELZI® (etanercept-szzs) | Sandoz | ENBREL® | Aug. 30, 2016 | No | Immunex v. Sandoz |
4 | AMJEVITA® (adalimumab-atto) | Amgen | HUMIRA® | Sept. 23, 2016 | No | AbbVie v. Amgen |
5 | RENFLEXIS® (infliximab-abda) | Samsung Bioepis | REMICADE® | Apr. 21, 2017 | No | None |
Last updated: May 3, 2017